S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.38
+4.5%
$1.82
$1.21
$7.97
$47.80M1.09148,261 shs66,774 shs
Bioventus Inc. stock logo
BVS
Bioventus
$4.55
-3.2%
$4.96
$0.86
$6.08
$360.22M0.5147,150 shs106,628 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$14.00
+1.8%
$14.59
$3.80
$18.15
$367.92M2.08106,465 shs65,350 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
-5.04%-7.04%-25.42%-33.67%-56.00%
Bioventus Inc. stock logo
BVS
Bioventus
+1.29%-5.43%-14.39%-1.67%+343.40%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-2.07%-5.30%+7.09%+3.77%+197.62%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
4.0886 of 5 stars
3.54.00.04.21.81.70.6
Bioventus Inc. stock logo
BVS
Bioventus
3.5044 of 5 stars
3.50.00.00.02.54.21.9
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.4282 of 5 stars
3.43.00.00.01.94.20.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17346.86% Upside
Bioventus Inc. stock logo
BVS
Bioventus
3.00
Buy$7.6768.50% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.86
Moderate Buy$15.6711.90% Upside

Current Analyst Ratings

Latest APYX, NPCE, and BVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
3/13/2024
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $9.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $13.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00
2/22/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $16.00
1/30/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/30/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.91N/AN/A$0.78 per share1.77
Bioventus Inc. stock logo
BVS
Bioventus
$512.34M0.70$0.78 per share5.87$2.80 per share1.63
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$65.42M5.62N/AN/A$0.79 per share17.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$2.52N/A11.38N/A-30.49%2.25%0.62%5/21/2024 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$32.96M-$1.28N/AN/AN/A-50.38%-153.76%-31.73%5/8/2024 (Confirmed)

Latest APYX, NPCE, and BVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.32N/A+$0.32N/AN/AN/A
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million
3/12/2024Q4 2023
Bioventus Inc. stock logo
BVS
Bioventus
$0.06$0.07+$0.01$0.24$124.84 million$135.42 million
3/5/2024Q4 2023
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.33-$0.23+$0.10-$0.23$17.74 million$18.01 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Bioventus Inc. stock logo
BVS
Bioventus
1.66
1.53
1.01
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.76
5.71
5.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Bioventus Inc. stock logo
BVS
Bioventus
29.10%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
27.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Bioventus Inc. stock logo
BVS
Bioventus
97079.17 million56.13 millionNot Optionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17126.28 million19.06 millionOptionable

APYX, NPCE, and BVS Headlines

SourceHeadline
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in Stock
marketbeat.com - April 18 at 6:51 PM
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
globenewswire.com - April 17 at 4:05 PM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 SharesNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 Shares
americanbankingnews.com - April 16 at 4:18 AM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in Stock
insidertrades.com - April 16 at 4:17 AM
Orbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOrbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock
marketbeat.com - April 15 at 6:47 PM
Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)
americanbankingnews.com - April 15 at 2:00 AM
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 14 at 4:08 AM
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from BrokeragesNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages
marketbeat.com - April 14 at 4:07 AM
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%
marketbeat.com - April 12 at 12:14 AM
NeuroPace (NASDAQ: NPCE)NeuroPace (NASDAQ: NPCE)
fool.com - April 10 at 3:47 PM
Kent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)Kent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)
marketbeat.com - April 6 at 7:28 PM
Biggest mistake bond investors may make ahead of Fed rate cuts'Biggest mistake' bond investors may make ahead of Fed rate cuts
msn.com - April 4 at 7:38 PM
NeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceNeuroPace to Present at the Needham 23rd Annual Healthcare Conference
globenewswire.com - March 27 at 4:05 PM
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
marketbeat.com - March 20 at 5:13 AM
The Latest Analyst Ratings For NeuroPaceThe Latest Analyst Ratings For NeuroPace
markets.businessinsider.com - March 13 at 5:40 AM
NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers
markets.businessinsider.com - March 7 at 1:04 PM
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 1:04 PM
NeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsNeuroPace Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 7 at 8:04 AM
NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 7 at 3:02 AM
Recap: NeuroPace Q4 EarningsRecap: NeuroPace Q4 Earnings
benzinga.com - March 6 at 5:01 PM
NeuroPace GAAP EPS of -$0.23NeuroPace GAAP EPS of -$0.23
msn.com - March 6 at 5:01 PM
NeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending ConcernsNeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending Concerns
markets.businessinsider.com - March 6 at 5:01 PM
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 MillionNeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
globenewswire.com - March 5 at 4:05 PM
Financial Freedom Fighters: 3 Stocks to Liberate Your PortfolioFinancial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
investorplace.com - March 5 at 2:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Bioventus logo

Bioventus

NYSE:BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
NeuroPace logo

NeuroPace

NASDAQ:NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.